

D25 Sub E1  
--40. (Amended) The method of claim 38, wherein the soluble B7 protein is the extracellular domain of B7 joined to at least a portion of an immunoglobulin molecule. --

Please add new claims 43-44 as follows:

D26  
--43. (new) The method of claim 38, wherein the extracellular domain of B7 begins at position 1 and ends at position 215 of SEQ ID NO.: 23. --

Sub E2  
--44. (new) The method of claim 40, wherein the soluble B7 protein is a B7Ig fusion protein. --

**In the Abstract**

Please amend the abstract of the subject application as follows:

Please delete the abstract, beginning "The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions." and replace it with the following rewritten abstract:

D27  
-- This invention provides methods for regulating T cell interactions with B7 positive cells. Methods are provided for using B7 antigen, its fragments and derivatives reactive with CTLA4 receptor, to regulate CTLA4 positive T cell responses, and immune responses mediated by T cells. --